期刊文献+

低浓度吉西他滨对肾癌786-0细胞免疫原性相关分子表达的影响

Effects of low dose gemcitabine on the expressions of immunogenic molecular related molecules on the surface of renal carcinoma cell 786-0
下载PDF
导出
摘要 目的:探讨低浓度吉西他滨(gemcitabine,GMC)对人肾透明细胞癌786-0细胞免疫原性相关钙网蛋白(calreticulin,CRT)、MHC-Ⅰ/Ⅱ表达变化的影响。方法:依据药物浓度分为4组,用流式细胞仪检测各组细胞CRT、MHC-Ⅰ、MHC-Ⅱ分子的表达。结果:低浓度GMC可使CRT、MHC-Ⅰ/Ⅱ荧光强度表达增强,与对照组比较,低浓度各组CRT、MHC-Ⅰ/Ⅱ表达量差异有统计学意义,组间比较差异均有统计学意义(P<0.01)。结论:低浓度GMC能够有效诱导人肾透明细胞癌免疫原性相关CRT、MHC-Ⅰ/Ⅱ的表达。 Objective To investigate the effect of low dose gemcitabine (GMC) on the expression of calreticulin (CRT) and MHC- Ⅰ/Ⅱ in the renal carcinoma cell 756-0. Methods Four groups were set up based on the gradient of drug concentration. The expressions of CRT and MHC-Ⅰ/Ⅱ were detected by the flow cytometry. Results Expression of CRT and MHC-Ⅰ/Ⅱ in the cell significantly increased in the low dose GMC groups than those in the control group(P 〈 0.01). Conclusion The low dose of GMC may effectively induce the expression of CRT and MHC-Ⅰ/Ⅱ in the renal clear cell.
出处 《实用医学杂志》 CAS 北大核心 2015年第3期367-369,共3页 The Journal of Practical Medicine
关键词 吉西他滨 免疫 细胞 Gemcitabine Immune Celluar
  • 相关文献

参考文献2

二级参考文献29

  • 1Dunn GP, Old IJ, Schreiber RD. The immunobiology of cancer immuuosurveillance and imrnunoediting, Immunity, 2004, 21: 137-148.
  • 2Chouaib S. Tumor escape[rom the immune response: a major hurdle for successful immunotherapy of cancer? Tunis Med, 2005, 83 :7-10.
  • 3Cardai SJ, McPhillips KA, Frasch SC, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of tRP on the phagocyte. Cell, 2005, 123: 321- 334.
  • 4Obeid M. ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of cal reticulin.J l mmunol , 2008,181 :2533-2543.
  • 5Obeid M. ERP57 Membrane Translocation Dictates the lmmunogenicity of Tumor Cell Death by Controlling the Membrane Translocation of Cal reticulin.J Immunol , 2008,181: 2533-2543.
  • 6Martelli M, Ferrerl A J, Agostinelli C, et al. New drugs for aggressive B-cell and T-cell lymphomas[J]. Crit Rev Oncol Hematol, 2013,87(2) : 146-171.
  • 7Gisselbrecht C, Mounier N. Improving second-llne therapy in aggressive non- Hedgkin's lymphoma [J]. Semin 0ncol,2004,31 ( 1 Suppl 2) : 12-16.
  • 8Reddy LH, Couvreur P. Novel approaches to deliver gemcitabine to cancers[J]. Curr Pharm Des,2008,14 (11):1124-1137.
  • 9Paola E D, Alonso S, Ginliani R, et al. An open-label, dose-fmding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors [J]. Front Oncol,2012,2: 175.
  • 10C, azzaniga P, Sflvestri I, C, redilone A, et al. C, emcitabine-induced apoptesis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer[ J]. Anticancer Drugs,2007,18 (2):179- 185.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部